Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase

Journal of Neurochemistry

Volumn 101, Issue 4, 2007, Pages 929-936

  Czech, Christian ^a   Burns, Mark P ^b   Vardanian, Lilit ^b   Augustin, Angelique ^a   Jacobsen, Helmut ^a   Baumann, Karlheinz ^a   Rebeck, G William ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abeta; Alzheimer's disease; Amyloid precursor protein; Cholesterol; Gamma secretase; Liver X receptor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; ENZYME INHIBITOR; GAMMA SECRETASE; LIVER X RECEPTOR AGONIST; METHYL BETA CYCLODEXTRIN; TO 901317; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; BETA-CYCLODEXTRINS; CELL LINE, TRANSFORMED; CHOLESTEROL; CRICETINAE; CRICETULUS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; PRESENILIN-1; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSFECTION;

EID: 34247633123     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04467.x     Document Type: Article

References (25)

1. Akiyama H., Barger S., Barnum S. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383 421.
2. Anthony J. C., Breitner J. C., Zandi P. P., Meyer M. R., Jurasova I., Norton M. C. Stone S. V. (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066 2071.
3. Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I. Shearman M. S. (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 43 419 43 426.
4. Bodovitz S. Klein W. L. (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436 4440.
5. Brockhaus M., Grunberg J., Rohrig S., Loetscher H., Wittenburg N., Baumeister R., Jacobsen H. Haass C. (1998) Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport 9, 1481 1486.
6. Burns M. P., Vardanian L., Pajoohesh-Ganji A., Wang L., Cooper M., Harris D. C., Duff K. Rebeck G. W. (2006) The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 98, 792 800.
7. Fukumoto H., Deng A., Irizarry M. C., Fitzgerald M. L. Rebeck G. W. (2002) Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 277, 48 508 48 513.
8. Kojro E., Gimpl G., Lammich S., Marz W. Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 5815 5820.
9. Koldamova R. P., Lefterov I. M., Staufenbiel M., Wolfe D., Huang S., Glorioso J. C., Walter M., Roth M. G. Lazo J. S. (2005) The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280, 4079 4088.
10. Kornilova A. Y., Bihel F., Das C. Wolfe M. S. (2005) The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc. Natl Acad. Sci. USA 102, 3230 3235.
11. Kukar T., Murphy M. P., Eriksen J. L. et al. (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 11, 545 550.
12. Li Y. M., Lai M. T., Xu M., Huang Q., DiMuzio-Mower J., Sardana M. K., Shi X. P., Yin K. C., Shafer J. A. Gardell S. J. (2000) Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc. Natl Acad. Sci. USA 97, 6138 6143.
13. Lleo A., Berezovska O., Herl L., Raju S., Deng A., Bacskai B. J., Frosch M. P., Irizarry M. Hyman B. T. (2004) Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 10, 1065 1066.
14. McGeer P. L., Schulzer M. McGeer E. G. (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425 432.
15. Oram J. F. Heinecke J. W. (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85, 1343 1372.
16. Repa J. J., Turley S. D., Lobaccaro J. A., Medina J., Li L., Lustig K., Shan B., Heyman R. A., Dietschy J. M. Mangelsdorf D. J. (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524 1529.
17. Rogers J., Kirby L. C., Hempelman S. R. et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609 1611.
18. Seiffert D., Bradley J. D., Rominger C. M. et al. (2000) Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem. 275, 34 086 34 091.
19. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460 6464.
20. Stewart W. F., Kawas C., Corrada M. Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626 632.
21. Sun Y., Yao J., Kim T. W. Tall A. R. (2003) Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem. 278, 27 688 27 694.
22. Takahashi Y., Hayashi I., Tominari Y., Rikimaru K., Morohashi Y., Kan T., Natsugari H., Fukuyama T., Tomita T. Iwatsubo T. (2003) Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem. 278, 18 664 18 670.
23. Wahrle S., Das P., Nyborg A. C., McLendon C., Shoji M., Kawarabayashi T., Younkin L. H., Younkin S. G. Golde T. E. (2002) Cholesterol-dependent [gamma]-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 11 23.
24. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212 216.
25. Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T. Selkoe D. J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513 517.